PMID- 26840083
OWN - NLM
STAT- MEDLINE
DCOM- 20171201
LR  - 20220316
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 10
DP  - 2016 Mar 8
TI  - Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription 
      through binding with EZH2, LSD1 in non small cell lung cancer.
PG  - 11696-707
LID - 10.18632/oncotarget.7077 [doi]
AB  - Long non-coding RNAs are emerging as crucial regulators and prognostic markers in 
      multiple cancers including non small cell lung cancer (NSCLC). In this study, we 
      screened LINCO1133 as a new candidate lncRNA which promotes NSCLC development and 
      progression, in two independent datasets (GSE18842 and GSE19804) from the Gene 
      Expression Omnibus (GEO). LINC01133 is previously found to be over-expressed in 
      lung squamous cell cancer (LSCC) and knockdown its expression inhibits LSCC cells 
      invasion. However, its' molecular mechanism and downstream targets involving in 
      regulation of cancer cells phenotype is not known. Here, we found that LINC01133 
      expression is up-regulated in NSCLC tissues, and its' over-expression is 
      associated with patients poor prognosis and short survival time. LINC01133 
      knockdown decreased NSCLC cells proliferation, migration, invasion and induced 
      cell cycle G1/S phase arrest and cell apoptosis. Mechanistic investigations 
      showed that LINC01133 could interact with EZH2, LSD1 and recruit them to KLF2, 
      P21 or E-cadherin promoter regions to repress their transcription. Furthermore, 
      rescue experiments demonstrated that LINC01133 oncogenic function is partly 
      through regulating KLF2. Lastly, we found that there was negative correlation 
      between LINC01133 and KLF2, P21 or E-cadherin in NSCLC. Overall, our findings 
      illuminate how LINC01133 over-expression confers an oncogenic function in NSCLC 
      that may offer a novel therapy target in this disease.
FAU - Zang, Chongshuang
AU  - Zang C
AD  - Department of Oncology, First Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - Nie, Feng-Qi
AU  - Nie FQ
AD  - Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - Wang, Qian
AU  - Wang Q
AD  - Department of Oncology, First Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - Sun, Ming
AU  - Sun M
AD  - Department of Biochemistry and Molecular Biology, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - Li, Wei
AU  - Li W
AD  - Department of Oncology, First Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - He, Jing
AU  - He J
AD  - Department of Oncology, First Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - Zhang, Meiling
AU  - Zhang M
AD  - Department of Oncology, First Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
FAU - Lu, Kai-Hua
AU  - Lu KH
AD  - Department of Oncology, First Affiliated Hospital, Nanjing Medical University, 
      Nanjing, People's Republic of China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antigens, CD)
RN  - 0 (CDH1 protein, human)
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cadherins)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (KLF2 protein, human)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (long non-coding RNA LINC01133, human)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 1.5.- (KDM1A protein, human)
RN  - EC 2.1.1.43 (EZH2 protein, human)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
SB  - IM
MH  - A549 Cells
MH  - Aged
MH  - Animals
MH  - Antigens, CD
MH  - Cadherins/biosynthesis/*genetics
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/physiology
MH  - Cyclin-Dependent Kinase Inhibitor p21/biosynthesis/*genetics
MH  - Enhancer of Zeste Homolog 2 Protein/*metabolism
MH  - Heterografts
MH  - Histone Demethylases/*metabolism
MH  - Humans
MH  - Kruppel-Like Transcription Factors/biosynthesis/*genetics
MH  - Lung Neoplasms/*genetics/metabolism/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Prognosis
MH  - RNA, Long Noncoding/*genetics
MH  - Transcription, Genetic
MH  - Transfection
PMC - PMC4905504
OTO - NOTNLM
OT  - EZH2
OT  - LSD1
OT  - NSCLC
OT  - lncRNA
OT  - proliferation
COIS- CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.
EDAT- 2016/02/04 06:00
MHDA- 2017/12/02 06:00
PMCR- 2016/03/08
CRDT- 2016/02/04 06:00
PHST- 2015/09/16 00:00 [received]
PHST- 2016/01/20 00:00 [accepted]
PHST- 2016/02/04 06:00 [entrez]
PHST- 2016/02/04 06:00 [pubmed]
PHST- 2017/12/02 06:00 [medline]
PHST- 2016/03/08 00:00 [pmc-release]
AID - 7077 [pii]
AID - 10.18632/oncotarget.7077 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Mar 8;7(10):11696-707. doi: 10.18632/oncotarget.7077.